Acorda Announces Initiation of Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking Deficits
Acorda Therapeutics, 15 Dec 2014
Accessed on 23 Dec 2014 from http://ir.acorda.com/investors/investor-news/investor-news-details/2014/Acorda-Announces-Initiation-of-Phase-3-Clinical-Trial-for-Dalfampridine-in-Post-Stroke-Walking-Deficits/default.aspx.